Tag: B-cell lymphoma

1. Entecavir showed a significant reduction in the incidence of hepatitis B virus reactivation compared to lamivudine when used as prophylaxis during R-CHOP therapy1 for diffuse large B cell lymphoma. 2. There was no significant difference between entecavir and lamivudine with regards to frequency and severity of adverse events. Evidence Rating...
1. The addition of lenalidomide to standard R-CHOP chemotherapy reduced the negative prognostic impact of non-GCB phenotype in diffuse large B-cell lymphoma (DLBCL) progression-free and overall survival. Evidence Rating Level: 1 (Excellent)  Study Rundown: Therapy for diffuse large B-cell lymphoma (DLBCL) has advanced in recent years with the introduction of dose-intensified...
1. The MYD88 mutation was associated with a shorter survival rate in primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT).  2. The MYD88 mutation was positive in 59% of patients with PCLBCL-LT and was associated with older initial presentation and had higher likelihood of leg involvement.  Evidence Rating Level: 2...
May 20 - 27, 2013 In this section, we will highlight the some of the high-impact studies, updates, and analyses published in medicine during the past week. Prone Positioning in Severe Acute Respiratory Distress Syndrome In this multicenter RCT (n = 465), patients with moderate to severe ARDS (<150mmHg PaO2/FiO2) were shown...